Relationship between serum IL-1β, IL-17 levels and the therapeutic effect in patients with first-episode schizophrenia
YAN Ci1 WANG Yanbo2
1.Department of Psychiatry, Hangzhou Seventh People′s Hospital, Zhejiang Province, Hangzhou 310000, China;
2.the Third Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou 310000, China
Abstract：Objective To explore the relationship between serum interleukin-1β (IL-1β), interleukin-17 (IL-17) levels and the therapeutic effect in patients with first-episode schizophrenia. Methods A total of 200 patients with first-episode schizophrenia admitted in Hangzhou Seventh People′s Hospital from January 2017 to January 2019 were selected as the research group. Olanzapine was given to the patients on the day of admission and the treatment time was 4 weeks. At the same time, sixty healthy people were selected as the control group. The positive and negative symptoms scale (PANSS) scores were recorded before and 4 weeks after treatment. The serum IL-1β and IL-17 levels of two groups were measured by enzyme-linked immunosorbent assay. According to the effective rate of treatment, the research group was divided into group A (recovery, 30 cases), group B (significant progress, 60 cases), group C (improvement, 72 cases) and group D (ineffective, 38 cases). The serum IL-1β and IL-17 levels were compared before and after treatment in each group. Pearson correlation was used to analyze the correlation between serum IL-1β, IL-17 levels and PANSS score in patients. Results The levels of serum IL-1β and IL-17 in the research group were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). The levels of serum IL-1β and IL-17 in the research group after treatment were significantly lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). Compared with before treatment in the same group, the serum levels of IL-1β in groups A, B and C were significantly reduced, and the serum levels of IL-17 in groups A and B were significantly reduced, the differences were statistically significant (P ＜ 0.05). Further pairwise comparison, the differences in serum IL-1β levels of the four groups were statistically significant (P ＜ 0.05), and the level in group A was the lowest. In addition, the serum IL-17 levels in group A were significantly lower than those in the other three groups, and the serum IL-17 levels in group B were significantly lower than those in group D, and the differences were statistically significant (P ＜ 0.05). The levels of serum IL-1β and IL-17 were positively correlated with PANSS score（r = 0.386, 0.544, P ＜ 0.05）. Conclusion IL-1β and IL-17 are closely related to the onset of schizophrenia, which can reflect the therapeutic effect to a certain extent, and have an important value in evaluating clinical effect of patients.
严辞1 汪彦博2. 血清IL-1β、IL-17水平与首发精神分裂症患者治疗效果的关系[J]. 中国医药导报, 2019, 16(36): 178-封三.
YAN Ci1 WANG Yanbo2. Relationship between serum IL-1β, IL-17 levels and the therapeutic effect in patients with first-episode schizophrenia. 中国医药导报, 2019, 16(36): 178-封三.
2019, Vol. 16 
京公网安备 11010502046598号